After-Hours Movers 05/30: (ENVI) (TLYS) Higher; (LGF) (BMRN) (TIVO) (AONE) Lower
Tweet
Share
E-mail
Get Alerts LGF Hot Sheet
Join SI Premium – FREE
Lions Gate Ent. (NYSE: LGF) 6.9% LOWER; reported Q4 EPS of ($0.17), versus $0.34 reported last year. Revenue for the quarter came in at $645.2 million versus the consensus estimate of $618.81 million.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) 3.9% LOWER; is offering to sell 6,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 650,000 shares of common stock.
Envivio (NASDAQ: ENVI) 3.4% HIGHER; reported Q1 EPS of ($0.12), $0.06 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $13 million. Sees Q2 2012 EPS of $-0.02-$0.02, versus the consensus of $0.00. Sees Q2 2012 revenue of $17-$18 million, versus the consensus of $16.67 million.
Tivo, Inc. (NASDAQ: TIVO) 3% LOWER; reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.5 million versus the consensus estimate of $54.89 million.
Tillys (NYSE: TLYS) 2% HIGHER; reported Q1 EPS of $0.18, versus $0.14 reported last year. Revenue for the quarter came in at $96.52 million, versus $83.13 million reported last year.
A123 Systems (Nasdaq: AONE) 1.7% LOWER; the company has filed a "Going Concern" statement in a Form 8-K this afternoon. The company cited the battery pack replacement plan and said it sees "significant" losses over the next several quarters. The company is assessing actions to raise capital.
Alkermes plc (NASDAQ: ALKS) 1.5% LOWER; today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients. ALKS 37 was generally well tolerated at all dose levels, and while subjects taking ALKS 37 demonstrated an increase in bowel movements compared to baseline, the product profile did not satisfy our pre-specified criteria for advancing into phase 3 clinical trials. Based on this evaluation, Alkermes has decided not to advance ALKS 37 and will consider out-licensing opportunities.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) 3.9% LOWER; is offering to sell 6,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 650,000 shares of common stock.
Envivio (NASDAQ: ENVI) 3.4% HIGHER; reported Q1 EPS of ($0.12), $0.06 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $13 million. Sees Q2 2012 EPS of $-0.02-$0.02, versus the consensus of $0.00. Sees Q2 2012 revenue of $17-$18 million, versus the consensus of $16.67 million.
Tivo, Inc. (NASDAQ: TIVO) 3% LOWER; reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.5 million versus the consensus estimate of $54.89 million.
Tillys (NYSE: TLYS) 2% HIGHER; reported Q1 EPS of $0.18, versus $0.14 reported last year. Revenue for the quarter came in at $96.52 million, versus $83.13 million reported last year.
A123 Systems (Nasdaq: AONE) 1.7% LOWER; the company has filed a "Going Concern" statement in a Form 8-K this afternoon. The company cited the battery pack replacement plan and said it sees "significant" losses over the next several quarters. The company is assessing actions to raise capital.
Alkermes plc (NASDAQ: ALKS) 1.5% LOWER; today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients. ALKS 37 was generally well tolerated at all dose levels, and while subjects taking ALKS 37 demonstrated an increase in bowel movements compared to baseline, the product profile did not satisfy our pre-specified criteria for advancing into phase 3 clinical trials. Based on this evaluation, Alkermes has decided not to advance ALKS 37 and will consider out-licensing opportunities.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper remains bullish on this beverage stock, citing 'best-in-class execution'
- China tech giant’s AI bet faces test as cloud growth accelerates
- Barclays flags an "attractive entry point" in this pharma stock
Create E-mail Alert Related Categories
Special ReportsRelated Entities
After-Hours MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
